PRF1 and neoplasm: Anti-tumor therapies, including recent novel approaches, targeted agents and cytotoxic T cell-centered immunotherapies eliminate malignant cells through diverse mechanisms: disrupting oncogenic signaling or directly damaging tumor cell structure (perforin pores, cytoskeleton degradation, DNA damage, nuclear envelope rupture, reactive oxygen species (ROS)-induced ER stress or mitochondrial stress, et al.)51.